(2S)-2-[(1S)-1-[(1S,3R,8S,9S,10R,13S,14S,17R)-1,3-dihydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethyl]-5-(hydroxymethyl)-4-methyl-2,3-dihydropyran-6-one | 1185317-46-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (2S)-2-[(1S)-1-[(1S,3R,8S,9S,10R,13S,14S,17R)-1,3-dihydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethyl]-5-(hydroxymethyl)-4-methyl-2,3-dihydropyran-6-one
• CAS: 1185317-46-7
• 化学式: C₂₈H₄₂O₅
• 分子量: 458.638
• InChiKey: FYYIHVSEGVWNCF-HXFMLCQMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  33
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  87
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  在 氟化氢吡啶 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 以84%的产率得到(2S)-2-[(1S)-1-[(1S,3R,8S,9S,10R,13S,14S,17R)-1,3-dihydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethyl]-5-(hydroxymethyl)-4-methyl-2,3-dihydropyran-6-one
  参考文献：
  名称：

  Synthesis of Sominone and Its Derivatives Based on an RCM Strategy: Discovery of A Novel Anti-Alzheimer’s Disease Medicine Candidate “Denosomin”

  摘要：

  Synthesis of sominone was achieved starting from dehydroepiandrosterone on the basis of an RCM strategy for the construction of a delta-lactone side chain. This synthetic protocol was applied for the synthesis of several analogous derivatives including 1-deoxy-24-norsominone (denosomin), which was revealed to exhibit notable bioactivities for new antidementia chemotherapy, exceeding the original natural compound sominone.

  DOI：

  10.1021/ol901553w

文献信息

• [EN] NOVEL SOMINONE DERIVATIVE<br/>[FR] NOUVEAU DÉRIVÉ DE SOMINONE
  申请人：LEAD CHEM CO LTD

  公开号：WO2010041681A1

  公开（公告）日：2010-04-15

  【課題】神経疾患の予防治療剤として有用な新規化合物を提供することを目的とする。 【解決手段】次式（１）で表されるソミノン誘導体又はその塩。

  【问题】旨在提供作为神经疾病预防治疗药物的有用新化合物。 【解决方法】表示为式（1）的Somino衍生物或其盐。
• Synthesis of Sominone and Its Derivatives Based on an RCM Strategy: Discovery of A Novel Anti-Alzheimer’s Disease Medicine Candidate “Denosomin”
  作者：Yuji Matsuya、Yu-ichiro Yamakawa、Chihiro Tohda、Kiyoshi Teshigawara、Masashi Yamada、Hideo Nemoto

  DOI：10.1021/ol901553w

  日期：2009.9.3

  Synthesis of sominone was achieved starting from dehydroepiandrosterone on the basis of an RCM strategy for the construction of a delta-lactone side chain. This synthetic protocol was applied for the synthesis of several analogous derivatives including 1-deoxy-24-norsominone (denosomin), which was revealed to exhibit notable bioactivities for new antidementia chemotherapy, exceeding the original natural compound sominone.